Researchers at Georgia State University have designed a protein that can effectively target a cell surface receptor linked to a number of diseases, including cancer. The researchers believe this synthetic protein, which they named ProAgio, has the potential to be a therapeutic treatment for various illnesses. Their work was recently published in Nature Communications. The
Type 1 diabetes (T1D) is an autoimmune disease where an individual’s immune cells destroy the beta cells of the pancreas. Beta cells are responsible for the production and secretion of insulin, a hormone that allows the body to use or store glucose from foods. People with T1D suffer from high blood glucose that can result
Here at Kerafast, we recently added the first monobody products to our catalog, prompting us to ask the question: what exactly is a monobody? Monobodies, as it turns out, are actually synthetic binding proteins. Based on a molecular scaffold composed of a fibronection type III domain (FN3), they are an alternative to traditional antibodies, belonging